[Mucosal complication of cutaneous leishmaniasis].
A 74-year-old man from the rural area of Caicedonia, Valle del Cauca Province, was diagnosed with uncontrolled hypertension, stage IV chronic renal failure and severe anemia. Fifteen years earlier, while living in Guaviare Province, he was diagnosed with leishmaniasis-with lesions located on the right upper and lower eyelids, left auricle and limbs. At that time, he received an incomplete treatment with antimonials. The patient had experienced 8 years of progressive mucosal lesions located in the upper lip, nasal mucosa and right upper and lower eyelids (figure 1). A histopathological diagnosis of leishmaniasis was made and confirmed by polymerase chain reaction (figure 2). Treatment with antimonials (Glucantime) was contraindicated due to the patient's comorbidities. Inpatient supervised treatment with miltefosine (Impavido 50 mg capsules) was initiated according to the national guidelines of 1.8 mg/kg/day for 28 days. Clinical follow up and routine laboratory tests (creatinine, BUN, liver function tests and complete blood counts) were done during and after treatment; no complications were reported. Medical follow up was continued until the Internal medicine, ophthalmology, and plastic surgery consultations were provided for subsequent management of the pathology. Mucocutaneous leishmaniasis is a serious preventable complication of cutaneous leishmaniasis. This case illustrated a failure in opportune diagnosis and treatment of this disease as a consequence of an inadequate leishmaniasis control program. The case indicated the effectiveness of miltefosine as a therapeutic option in patients for whom antimonial treatment is contraindicated.
Zea
Diego Fernando
DF
Unidad Clínica, Centro Internacional de Entrenamiento e Investigaciones Médicas-CIDEIM, Call, Colombia. dzea@cideim.org.co
Prager
Martín
M
Figueroa
Roger Adrian
RA
Miranda
María Consuelo
MC
D000368:Aged; D000740:Anemia / Q000150:complications; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D000075202:Contraindications; D005141:Eyelid Diseases / Q000188:drug therapy / Q000209:etiology / Q000469:parasitology; D006801:Humans; D006973:Hypertension / Q000150:complications; D007676:Kidney Failure, Chronic / Q000150:complications; D016773:Leishmaniasis, Cutaneous / Q000150:complications* / Q000188:drug therapy; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy / Q000209:etiology*; D008047:Lip Diseases / Q000188:drug therapy / Q000209:etiology / Q000469:parasitology; D008297:Male; D008536:Meglumine; D000077485:Meglumine Antimoniate; D009668:Nose Diseases / Q000188:drug therapy / Q000209:etiology / Q000469:parasitology; D009942:Organometallic Compounds; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010767:Phosphorylcholine; C039128:miltefosine; D008536:Meglumine; D000077485:Meglumine Antimoniate